{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T14:05:17Z","timestamp":1762783517811,"version":"build-2065373602"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>We aimed to conduct a meta-analysis of randomized controlled trials (RCTs) to examine the efficacy of biologic DMARDs in improving the clinical response of patients with polyarticular JIA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The literature and relevant reviews were searched for published clinical studies comparing the efficacy of standard therapy without biologic DMARDs to that of biologic DMARDs in patients with polyarticular JIA. The focus was on the minimal clinical effectiveness criteria of the pediatric American College of Rheumatology (pedACR30\u2013100), time to disease flare, remission clinical, inactive disease, and pedACR30\/flare. This meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 9 randomized controlled trials were included in the study. Compared with standard therapy, treatment with biologics significantly improved PedACR70 (relative risk [RR] 1.68; 95% confidence interval [CI] 1.43\u20131.96;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001). Similarly, PedACR30 (RR 1.37; CI 1.19\u20131.58;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.0001), PedACR50 (RR 1.49; CI 1.25\u20131.77;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001), PedACR90 (RR 1.67; CI 1.34\u20132.09;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001) and PedACR100 (RR 1.88; CI 1.05\u20133.35;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03) were also significantly improved with biologic treatment. However, patients on standard therapy had worse flare outcomes, as determined by the PedACR30\/Flare (RR 0.56; CI 95% 0.45\u20130.70;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001). Additionally, the time to disease flare was significantly shorter with standard therapy (hazard ratio [HR] 0.38; 95% CI 0.27\u20130.54;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.00001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared with standard therapy, biologic DMARDs lead to significant and long-term improvements in signs and symptoms in polyarticular JIA patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>This meta-analysis was registered in PROSPERO under the registration number CRD42023494938 on December 18, 2023.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s42358-025-00488-x","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T14:02:14Z","timestamp":1762783334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of biologic DMARDs in improving the clinical response of patients with polyarticular juvenile idiopathic arthritis: a meta-analysis of RCTs"],"prefix":"10.1186","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9064-9046","authenticated-orcid":false,"given":"Pedro Henrique Aquino Gil","family":"de Freitas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9333-512X","authenticated-orcid":false,"given":"Mylena Maria Guedes","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2083-8022","authenticated-orcid":false,"given":"\u00c1urea Maria Salom\u00e3o","family":"Sim\u00e3o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-6024-3581","authenticated-orcid":false,"given":"Ana Beatriz","family":"Bertol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4825-7178","authenticated-orcid":false,"given":"Barkh\u00e1","family":"Vijendra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7900-1203","authenticated-orcid":false,"given":"Bianca Lisa","family":"de Faria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-9816","authenticated-orcid":false,"given":"Camila Maria Paiva Fran\u00e7a","family":"Telles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"488_CR1","unstructured":"Krumrey-Langkammerer M, H\u00e4fner R. Evaluation of the ILAR criteria for juvenile idiopathic arthritis. J. Rheumatol. 2001;28(11):2544\u20132547;. Available from: https:\/\/www.jrheum.org\/content\/28\/11\/2544.long"},{"issue":"10","key":"488_CR2","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1111\/1756-185X.14813","volume":"26","author":"K Chen","year":"2023","unstructured":"Chen K, et al. New classification criteria for juvenile idiopathic arthritis. Int J Rheumatic Dis. 2023;26(10):1899\u20131892. https:\/\/doi.org\/10.1111\/1756-185X.14813.","journal-title":"Int J Rheumatic Dis"},{"key":"488_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-021-00629-8","author":"LN Zaripova","year":"2021","unstructured":"Zaripova LN, et al. Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol. 2021. https:\/\/doi.org\/10.1186\/s12969-021-00629-8. 19 DOI.","journal-title":"Pediatr Rheumatol"},{"key":"488_CR4","doi-asserted-by":"publisher","unstructured":"Dave M, et al. Global prevalence estimates of three chronic musculoskeletal conditions: club foot, juvenile idiopathic arthritis and juvenile systemic lupus erythematosus. Pediatr Rheumatol. 2020;18. https:\/\/doi.org\/10.1186\/s12969-020-00443-8.","DOI":"10.1186\/s12969-020-00443-8"},{"key":"488_CR5","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1002\/acr.23870","volume":"71","author":"S Ringold","year":"2019","unstructured":"Ringold S, et al. 2019 American college of Rheumatology\/Arthritis foundation guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for Non-Systemic Polyarthritis, Sacroiliitis, and enthesitis. Arthritis Care Res. 2019;71:717\u201334. https:\/\/doi.org\/10.1002\/acr.23870.","journal-title":"Arthritis Care Res"},{"key":"488_CR6","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1056\/NEJM19920416326160","volume":"326","author":"EH Giannini","year":"1992","unstructured":"Giannini EH, et al. Methotrexate in resistant juvenile rheumatoid Arthritis \u2014 Results of the U.S.A.\u2013U.S.S.R. Double-Blind, Placebo-Controlled trial. N Engl J Med. 1992;326:1043\u20139. https:\/\/doi.org\/10.1056\/NEJM19920416326160.","journal-title":"N Engl J Med"},{"key":"488_CR7","doi-asserted-by":"publisher","unstructured":"Klein A et al. Efficacy and safety of oral and parenteral methotrexate therapy in children with juvenile idiopathic arthritis: an observational study with patients from the German methotrexate registry. Arthritis Care Res 2012 September;64:1349\u201356. https:\/\/doi.org\/10.1002\/acr.21697","DOI":"10.1002\/acr.21697"},{"key":"488_CR8","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1002\/art.30367","volume":"63","author":"M Bulatovi\u0107","year":"2011","unstructured":"Bulatovi\u0107 M, et al. High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthr Rhuem. 2011;63:2007\u201313. https:\/\/doi.org\/10.1002\/art.30367.","journal-title":"Arthr Rhuem"},{"key":"488_CR9","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00296-019-04385-7","volume":"39","author":"NA Ayaz","year":"2019","unstructured":"Ayaz NA, et al. Leflunomide treatment in juvenile idiopathic arthritis. Rheumatol Int. 2019;39:1615\u20139. https:\/\/doi.org\/10.1007\/s00296-019-04385-7.","journal-title":"Rheumatol Int"},{"key":"488_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1546-0096-12-13","volume":"12","author":"ML Stoll","year":"2014","unstructured":"Stoll ML, Cron RQ, et al. Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J. 2014;12:1\u201310. https:\/\/doi.org\/10.1186\/1546-0096-12-13.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"11","key":"488_CR11","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1056\/NEJM200003163421103","volume":"342","author":"DJ Lovell","year":"2000","unstructured":"Lovell DJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med. 2000;342(11):763\u20139. https:\/\/doi.org\/10.1056\/NEJM200003163421103.","journal-title":"N Engl J Med"},{"issue":"8","key":"488_CR12","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa0706290","volume":"359","author":"DJ Lovell","year":"2008","unstructured":"Lovell DJ, et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med. 2008;359(8):810\u201320. https:\/\/doi.org\/10.1056\/NEJMoa0706290.","journal-title":"N Engl J Med"},{"key":"488_CR13","doi-asserted-by":"publisher","unstructured":"Wallace CA et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. June 2012;64(6). https:\/\/doi.org\/10.1002\/art.34343","DOI":"10.1002\/art.34343"},{"key":"488_CR14","doi-asserted-by":"publisher","unstructured":"Brunner HI, et al. Efficacy and safety of Tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomized, double-blind withdrawal trial. Ann Rheum Dis. June 2015;74(6):1110\u20137. https:\/\/doi.org\/10.1136\/annrheumdis-2014-205351","DOI":"10.1136\/annrheumdis-2014-205351"},{"issue":"5","key":"488_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-020-00488-9","volume":"19","author":"E Alexeeva","year":"2021","unstructured":"Alexeeva E, et al. Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial. Pediatr Rheumatol Online J. 2021;19(5):1\u201312. https:\/\/doi.org\/10.1186\/s12969-020-00488-9.","journal-title":"Pediatr Rheumatol Online J"},{"issue":"10315","key":"488_CR16","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","volume":"398","author":"N Ruperto","year":"2021","unstructured":"Ruperto N, et al. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomized trial. Lancet. 2021;398(10315):1984\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(21)01255-1.","journal-title":"Lancet"},{"issue":"9","key":"488_CR17","doi-asserted-by":"publisher","first-page":"3096","DOI":"10.1002\/art.22838","volume":"56","author":"Ruperto","year":"2007","unstructured":"Ruperto, Nicolino, et al. A Randomized, Placebo-Controlled trial of Infliximab plus methotrexate for the treatment of Polyarticular-Course juvenile rheumatoid arthritis. Arthr Rhuem. 2007;56(9):3096\u2013106. https:\/\/doi.org\/10.1002\/art.22838.","journal-title":"Arthr Rhuem"},{"issue":"08","key":"488_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S0140","volume":"372","author":"Ruperto","year":"2008","unstructured":"Ruperto, Nicolino, et al. Abatacept in children with juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled withdrawal trial. Lancet. 2008;372(08):383\u201391. https:\/\/doi.org\/10.1016\/S0140.","journal-title":"Lancet"},{"key":"488_CR19","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1136\/annrheumdis-2016-210456","volume":"77","author":"Brunner","year":"2017","unstructured":"Brunner, Hermine, et al. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicenter, double-blind, randomized withdrawal trial. Ann Rheum Dis. 2017;77:21\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210456.","journal-title":"Ann Rheum Dis"},{"key":"488_CR20","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1002\/art.41390","volume":"72","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, et al. New medications are needed for children with juvenile idiopathic arthritis. Arthritis Rheumatol. 2020;72:1945\u201351. https:\/\/doi.org\/10.1002\/art.41390.","journal-title":"Arthritis Rheumatol"},{"key":"488_CR21","doi-asserted-by":"publisher","unstructured":"Consolaro A, et al. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. Lancet Child Adolesc Health. 2019 April;3(4):255\u201363. https:\/\/doi.org\/10.1016\/S2352-4642(19)30027-6.","DOI":"10.1016\/S2352-4642(19)30027-6"},{"key":"488_CR22","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"488_CR23","doi-asserted-by":"publisher","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, et al. The cochrane collaboration\u2019s tool for assessing risk of bias in randomized trials. BMJ. 2011;343:d5928. Published 2011 Oct 18. https:\/\/doi.org\/10.1136\/bmj.d5928","DOI":"10.1136\/bmj.d5928"},{"key":"488_CR24","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1093\/ajhp\/49.9.2229","volume":"49","author":"SC Hartwig","year":"1992","unstructured":"Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Health Syst Pharm. 1992;49:2229\u201332. https:\/\/doi.org\/10.1093\/ajhp\/49.9.2229.","journal-title":"Am J Health Syst Pharm"},{"key":"488_CR25","doi-asserted-by":"publisher","unstructured":"Amarilyo G, et al. Biological agents in polyarticular juvenile idiopathic arthritis: a meta-analysis of randomized withdrawal trials. Semin Arthritis Rheum. 2016 December;46(3):312\u20138. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.07.001.","DOI":"10.1016\/j.semarthrit.2016.07.001"},{"issue":"6","key":"488_CR26","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1345\/aph.1Q756","volume":"46","author":"K Decelle","year":"2012","unstructured":"Decelle K, Horton ER, et al. Tocilizumab for the treatment of juvenile idiopathic arthritis. Ann Pharmacother. 2012;46(6):822\u20139. https:\/\/doi.org\/10.1345\/aph.1Q756.","journal-title":"Ann Pharmacother"},{"key":"488_CR27","doi-asserted-by":"publisher","unstructured":"Lovell DJ, et al. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate. RMD Open. 2020 July;6(2). https:\/\/doi.org\/10.1136\/rmdopen-2020-001208.","DOI":"10.1136\/rmdopen-2020-001208"},{"issue":"3","key":"488_CR28","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/art.41528","volume":"73","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, et al. Efficacy and safety of Tocilizumab for Polyarticular-Course juvenile idiopathic arthritis in the Open-Label Two-Year extension of a phase III trial. Arthritis Rheumatol. 2020;73(3):530\u201341. https:\/\/doi.org\/10.1002\/art.41528.","journal-title":"Arthritis Rheumatol"},{"key":"488_CR29","doi-asserted-by":"publisher","unstructured":"Nagy A, et al. The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children: a meta-analysis. Pediatr Rheumatol. 2019 Jan 18 [cited 2024 Jul 24];17(4):530\u2013541. https:\/\/doi.org\/10.1186\/s12969-019-0305-x","DOI":"10.1186\/s12969-019-0305-x"},{"key":"488_CR30","doi-asserted-by":"publisher","unstructured":"Johnson CJ, et al. Etanercept in juvenile rheumatoid arthritis. Ann. Pharmacother. April 2001;35(4):464\u2013471. https:\/\/doi.org\/10.1345\/aph.10123. Available from: https:\/\/journals.sagepub.com\/doi\/abs\/10.1345\/aph.10123","DOI":"10.1345\/aph.10123"},{"issue":"11","key":"488_CR31","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1002\/acr.20283","volume":"62","author":"N Ruperto","year":"2010","unstructured":"Ruperto N, et al. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res. 2010;62(11):1542\u201351. https:\/\/doi.org\/10.1002\/acr.20283.","journal-title":"Arthritis Care Res"},{"key":"488_CR32","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/acr.24384","volume":"73","author":"HI Brunner","year":"2020","unstructured":"Brunner HI, et al. Functional ability and health-related quality of life in randomized controlled trials of tocilizumab in patients with juvenile idiopathic arthritis. Arthritis Care Res. 2020;73:1264\u201374. https:\/\/doi.org\/10.1002\/acr.24384.","journal-title":"Arthritis Care Res"},{"key":"488_CR33","doi-asserted-by":"publisher","unstructured":"Bharucha KN, et al. Growth during tocilizumab therapy for polyarticular-course juvenile idiopathic arthritis: 2-year data from a phase III clinical trial. J Rheumatol 2018 August;45(8):1173\u20139. https:\/\/doi.org\/10.3899\/jrheum.170326","DOI":"10.3899\/jrheum.170326"},{"key":"488_CR34","doi-asserted-by":"publisher","unstructured":"Brunner HI, et al. Functional ability and health-related quality of life in randomized controlled trials of tocilizumab in patients with juvenile idiopathic arthritis. Arthritis Care Res 2021 September;73(9):1264\u201374. https:\/\/doi.org\/10.1002\/acr.24384","DOI":"10.1002\/acr.24384"},{"key":"488_CR35","doi-asserted-by":"publisher","unstructured":"Shepherd J, et al. The clinical effectiveness and cost-effectiveness of abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis: a systematic review and economic evaluation. Health Technol Assess. 2016 April;20(34):1\u2013222. https:\/\/doi.org\/10.3310\/hta20340.","DOI":"10.3310\/hta20340"},{"issue":"5","key":"488_CR36","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1136\/annrheumdis-2016-210324","volume":"76","author":"MJ Ombrello","year":"2017","unstructured":"Ombrello MJ, et al. Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Ann Rheum Dis. 2017;76(5):906\u201313. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210324.","journal-title":"Ann Rheum Dis"}],"container-title":["Advances in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-025-00488-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42358-025-00488-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42358-025-00488-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T14:02:15Z","timestamp":1762783335000},"score":1,"resource":{"primary":{"URL":"https:\/\/advancesinrheumatology.biomedcentral.com\/articles\/10.1186\/s42358-025-00488-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["488"],"URL":"https:\/\/doi.org\/10.1186\/s42358-025-00488-x","relation":{},"ISSN":["2523-3106"],"issn-type":[{"value":"2523-3106","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors have declared no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Competing interests"}},{"value":"not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics, consent to Participate, and consent to publish declarations"}}],"article-number":"55"}}